Dr. Chao-Hui Yang and his team at Kaohsiung Chang Gung Memorial Hospital have successfully developed an innovative treatment for hearing loss using Toll-like receptor 9 (TLR9) antagonists, such as quinine-based medications. This approach reduces inner ear inflammation and protects hair cells, significantly improving hearing in patients with acute sensorineural hearing loss.

The Hidden Threat of Hearing Loss

Acute sensorineural hearing loss, including noise-induced hearing loss and sudden deafness, affects hundreds of millions worldwide. High-dose steroids remain the most common treatment, but their inconsistent efficacy and significant side effects put patients at risk of permanent hearing loss. Dr. Yang’s team offers a groundbreaking alternative that helps patients overcome the limitations of traditional therapies and improves their quality of life.

Efficacy and Cost Advantages

The innovative aspect of this therapy lies in suppressing inner ear inflammation to protect hair cells. Experimental results demonstrate that TLR9 antagonists reduce the expression of cytokine and chemokine genes in the cochlea following noise exposure, significantly decreasing NF-κB activation and macrophage infiltration. Animal studies showed that mice treated with quinine-based drugs experienced less hearing loss compared to control groups. Furthermore, clinical research revealed abnormal TLR9 expression in the leukocytes of patients with sudden hearing loss, further supporting the therapeutic potential of this approach.

This treatment not only delivers significant efficacy but also offers advantages over traditional steroid therapy, including fewer side effects and reduced costs. For instance, hydroxychloroquine, priced at only 3 New Taiwan Dollars per dose, is far more affordable than hearing aids or cochlear implants, greatly easing patients’ financial burden. Additionally, by reducing reliance on steroids, it minimizes associated risks, providing a safer and more cost-effective option for patients.

Pioneering the Future of Hearing Treatment

Dr. Yang highlighted that the technology is currently undergoing clinical trials. Future plans include collaborating with industry partners to develop novel small-molecule drugs for direct inner-ear administration. With its broad application potential, from soldiers and workers exposed to high-noise environments to patients with sudden hearing loss, this therapy stands to benefit a wide range of individuals.

According to market research, the global market for hearing loss treatment is steadily growing. This innovative therapy is poised to meet market demands and lead advancements in otological treatment technologies.

Resource: 類固醇外新選擇 類鐸受體9拮抗劑搶救突發性耳聾更安全